文拉法辛治疗糖尿病神经病变性疼痛的疗效及安全性  

Efficacy and safety of venlafaxine in diabetic neuropathic pain

作　　者：汪志红[1] 李启富[1] 刘秀容[1] 刘隆田[1] 张素华[1] 张兰英[1] 邓吉容[1] 

机构地区：[1]重庆医科大学附属第一医院内分泌科,400016

出　　处：《重庆医学》2006年第10期879-880,883,共3页Chongqing medicine

摘　　要：目的 评价文拉法辛治疗糖尿病神经病变性疼痛的临床疗效和安全性。方法 将43例糖尿病神经病变性疼痛患者随机分为两组，分别口服文拉法辛（21例，50mg／d）和卡马西平（22例，200mg／d），进行随机、双盲对照研究，疗程2周。采用0～10数字强度分级法、0～10数字表法及不良反应量表评定疗效和安全性。结果 （1）文拉法辛对疼痛缓解的疗效优于卡马西平（P=0．0001），其临床控制率、总有效率和获益率分别为25％、80％、100％和0％、30％、70％；（2）文拉法辛对生活质量改善的疗效优于卡马西平（P=0．0007）；（3）两药不良反应的差异无统计学意义。结论 本研究提示文拉法辛治疗糖尿病神经病变性疼痛是安全有效的，可适用于糖尿病神经病变性疼痛患者。Objective To access the efficacy and safety of venlafaxine in the treatment of diabetic neuropathic pain. Methods After a five-day wash-out period, 43 patients were randomized into two groups, receiving venlafaxine capsules and carbamazepine tablets respectively for two weeks. To evaluate, the efficacy and safety of venlafaxine,0-10 Numeric Pain Intensity Scale and 0-10 Numeric Rating Scale were used. Results （1） The efficacy of venlafaxine on relieving pain was significantly better than that of carbamazepine （P= 0. 000 1）. The clinical control, total effect and improvement rates were 25%, 80%, 100% for venlafaxine and 0%, 30%, 70% for carbamazepine. （2）The efficacy of venlafaxine on quality of life was significantly better than that of carbamazepine（P=0. 0007）. （3）There was no statistically significant difference about adverse effects between the two groups. Conclusion The results suggest that venlafaxine is safe and effective for treatment of patients with diabetic neuropathic pain.

关 键 词：糖尿病神经病变 疼痛 文拉法辛 卡马西平 

分 类 号：R587.2[医药卫生—内分泌]